Proteome-wide Mendelian randomization implicates nephronectin as an actionable mediator of the effect of obesity on COVID-19 severity

Satoshi Yoshiji[1,2,3,4], Guillaume Butler-Laporte[1,5], Tianyuan Lu[1,6], Julian Daniel Sunday Willett[1,6], Chen-Yang Su[1,7], Tomoko Nakanishi[1,2,3,4], David Morrison[1], Yiheng Chen[1,2], Kevin Liang[1,5], Michael Hultström[1,8], Zaman Afrasiabi[1], Shanshan Lan[1], Naomi Duggan[1], Chantal DeLuca[1], Mitra Vaezi[1], Chris Tselios[1], Xiaoqing Xue[1], Meriem Bouab[1], Fangyi Shi[1], Laetitia Laurent[1], Hans Markus Münter[9], Marc Afilalo[1,10], Jonathan Afilalo[1,5,11], Vincent Mooser[2,9], Nicholas J Timpson[12], Hugo Zeberg[13,14], Sirui Zhou[1,2,9], Vincenzo Forgetta[1,15], Yossi Farjoun[1,15], J. Brent Richards[1,2,5,15,16*]

[1] Lady Davis Institute, Jewish General Hospital, McGill University, Montréal, Québec, Canada
[2] Department of Human Genetics, McGill University, Montréal, Québec, Canada
[3] Kyoto-McGill International Collaborative Program in Genomic Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan
[4] Japan Society for the Promotion of Science, Japan
[5] Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montréal, Québec, Canada
[6] Quantitative Life Sciences Program, McGill University, Montréal, Québec, Canada
[7] Department of Computer Science, McGill University, Montréal, Québec, Canada
[8] Anaesthesiology and Intensive Care Medicine, Department of Surgical Sciences, Uppsala University, Sweden
[9] McGill Genome Centre, McGill University, Montréal, Québec, Canada
[10] Department of Emergency Medicine, Jewish General Hospital, McGill University, Montréal, Québec, Canada
[11] Division of Cardiology, Jewish General Hospital, McGill University, Montréal, Québec, Canada
[12] MRC Integrative Epidemiology Unit, University of Bristol, Bristol, United Kingdom
[13] Max Planck Institute for Evolutionary Anthropology, Leipzig, Germany
[14] Department of Neuroscience, Karolinska Institute, Stockholm, Sweden
[15] 5 Prime Sciences, Montréal, Québec, Canada
[16] Department of Twin Research, King's College London, London, United Kingdom

*Correspondence:
J. Brent Richards
Professor of Medicine, McGill University, Senior Lecturer, King's College London (Honorary), Pavilion H-413, Jewish General Hospital, 3755 Côte-Ste-Catherine Montréal, Québec, H3T 1E2, Canada.
Tel: +1-514-340-8222   Fax: +1-514-340-7529

Abstract

Obesity is a major risk factor for COVID-19 severity; however, the underlying mechanism is not fully understood. Considering that obesity influences the human plasma proteome, we sought to identify circulating proteins mediating the effects of obesity on COVID-19 severity. We first screened 4,907 plasma proteins to identify proteins influenced by body mass index (BMI) using Mendelian randomization (MR). This yielded 1,216 proteins, whose effects on COVID-19 severity were assessed, again using MR. This two-step approach identified nephronectin (NPNT), for which a one standard deviation increase was associated with severe COVID-19 (odds ratio = 1.71, 95% CI: 1.45–2.02, P = 1.63 × 10^{-10}). Colocalization analyses indicated that an NPNT splice isoform drove this effect. Overall, NPNT mediates 3.7% of the total effect of BMI on severe COVID-19. Finally, we found that decreasing body fat mass and increasing fat-free mass can lower NPNT levels and thus may improve COVID-19 outcomes. These findings provide actionable insights into how obesity influences COVID-19 severity.

Introduction

Coronavirus disease (COVID-19) has claimed more than 6 million lives globally since the start of the pandemic[1], and obesity increases the risk of severe COVID-19[2,3]. To date, multiple pathways have been explored as mechanisms linking obesity to COVID-19 severity, including metabolic abnormalities, systemic inflammation, and respiratory dysfunction (e.g., impaired gas exchange)[3-5]. However, the underlying mediators through which obesity influences COVID-19 outcomes are not fully understood. One strategy for disentangling this relationship is to identify circulating proteins mediating the effects of obesity on COVID-19 outcomes. As circulating proteins can be measured and, in some cases modulated, identification of mediator proteins may provide insights on the pathways whereby obesity increases the risk of severe COVID-19 and offer potential targets for therapeutic interventions.

A previous large cross-sectional study showed that body mass index (BMI) is significantly associated with changes in the plasma levels of 1,576 proteins[6], and another study supported the considerable influence of obesity on the plasma proteome[7]. However, as proteins are intricately involved in complex biological processes, observational studies may be biased by unmeasured confounding factors and reverse causation. Considering that COVID-19 has been associated with substantial changes in the levels of circulating proteins[8], the effects of circulating proteins on COVID-19 severity are also subject to such biases.

Mendelian randomization (MR) can help to protect against these biases. MR is a method that uses genetic variants as instrument variables to evaluate the causal effects of exposures (risk factors) on outcomes. As genetic variants are randomly allocated at the time of conception, they are largely independent of environmental and other potential confounders, thereby decreasing the risk of confounding. Additionally, they are not subject to reverse causation as the allocation of genetic variants always precedes the onset of diseases[9,10].

From the beginning of the pandemic, MR has played a critical role in providing evidence of modifiable risk factors for COVID-19[2,11,12]. Furthermore, multiple MR studies identified potential therapeutic targets for COVID-19, including OAS1, ABO, IFNAR2, IL-6, ELF5, and FAS[12-18]. Indeed, some MR findings have been validated by randomized controlled trials, demonstrating the utility of MR[19-24].

Notably, MR is based on several instrumental variable assumptions:[9,10] (I) the genetic

variants used as instrumental variables are associated with the exposure; (II) they are not

associated with factors that confound the relationship between the exposure and the outcome

and; (III) they influence the outcome only through exposure (also known as a lack of horizontal

pleiotropy). The most problematic of these assumptions is the last one; consequently, careful

assessment of horizontal pleiotropy is required. Nevertheless, with proper use, MR can serve as

a powerful tool to help understand the causal mechanisms in humans[9,10], and in the case of

obesity and COVID-19, can be used to screen thousands of proteins that may help to explain this

relationship.

Here, we integrated proteome-wide MR using the large-scale aptamer-based plasma

protein measurements, multiple sensitivity analyses, mediation analysis, colocalization, fine-

mapping, and single-cell RNA-sequencing analysis to identify plasma proteins mediating the

effect of BMI on COVID-19 severity.

Results

Study overview

The study was conducted in the following manner (**Figure 1**):

1) **Step 1 MR**: We performed two-sample MR to estimate the effect of BMI on circulating

protein levels using BMI genome-wide association study (GWAS) data for 694,649

individuals from GIANT and UK Biobank by Yengo *et al*.[25] in addition to the largest

proteomic GWAS data from the deCODE study[26] that measured plasma protein

abundance using 4907 aptamers in 35,559 individuals. Hereafter, "protein" is used when

referring to an aptamer targeting a protein[26].

2) **Step 2 MR**: Next, we performed two-sample MR to estimate the causal effects of the

above-identified proteins (BMI-driven proteins) on COVID-19 outcomes. To ensure that

the MR findings were not biased by linkage disequilibrium (LD), we used colocalization

analyses to evaluate whether the cis-acting protein quantitative loci (cis-pQTLs) of the

identified proteins and COVID-19 outcomes shared the same causal variant. For validation,

we repeated MR using cis-pQTLs from two independent studies (the FENLAND study[27]

and the AGES Reykjavik study[28]). For nephronectin (NPNT), which was robustly

associated with COVID-19 severity, we also investigated the consistency between MR

findings and observational associations between BMI and NPNT and NPNT and COVID-

19 using independent cohorts.

3) **Mediation analysis**: for NPNT, we performed an MR mediation analysis to quantify the
extent to which the total effect of BMI on severe COVID-19 was mediated by plasma NPNT
levels.
4) **Follow-up analysis for NPNT**: Furthermore, to better understand whether the total levels
of the NPNT protein, NPNT transcripts, or NPNT splice isoforms influenced COVID-19
severity, we performed colocalization analyses to identify whether the same causal variant
was shared between COVID-19 severity and NPNT protein level, NPNT transcript level,
and NPNT splice isoform level. Moreover, we analyzed single-cell RNA-sequencing data
of the lung autopsy samples from patients who died due to COVID-19 to gain insights into
the biological role of NPNT. Finally, we estimated the independent causal effect of body
fat and fat-free mass on plasma NPNT levels to identify a way of modulating plasma NPNT
levels.
131
Identifying the effects of BMI on plasma proteins (Step 1 MR)
We performed a two-sample MR using BMI as the exposure and 4,907 plasma protein levels as
the outcomes (see **Methods** and **Supplementary Table 1** for details). Out of 4,907 proteins
screened, 1,304 were estimated to be influenced by BMI using a Bonferroni-adjusted threshold
of $P < 1.0 \times 10^{-5}$ (0.05/4907), highlighting the substantial influence of obesity on plasma protein
levels (**Figure 2**). Among them, 1,229 proteins showed no apparent sign of horizontal pleiotropy
using the MR Egger test[29] ($P_{\text{Egger intercept}} > 0.05$) (**Supplementary Table 2)**.
139
To assess potential reverse causation, whereby the proteins influenced BMI, we performed a
bidirectional MR that used protein levels as exposures and BMI as the outcome (see **Methods**).
Thirteen proteins exhibited bidirectional effects (**Supplementary Table 3**) and were excluded
from further analyses. Hence, a total of 1,216 protein levels were identified as BMI-driven
proteins, which were estimated to be influenced by BMI with no detectable horizontal pleiotropy
or reverse causation. These protein levels, including NPNT and HSD17B14 (hydroxysteroid 17-
beta dehydrogenase 14), were used as exposures in the second step of our study.
147
Identifying the effects of BMI-driven proteins on COVID-19 severity (Step 2 MR)
Next, we evaluated the causal effects of the above-obtained, BMI-driven proteins on COVID-19
outcomes. We used cis-acting protein quantitative loci (cis-pQTLs) for these proteins as
instrumental variables and COVID-19 outcomes from the COVID-19 Host Genetics Initiative
GWASs (release 7)[2] as outcomes (**Supplementary Table 1)**. We did so to protect against bias

from horizontal pleiotropy. This is because cis-pQTLs reside near the transcription start site of the

protein-coding gene and are more likely to directly influence the protein levels than the trans-

pQTLs, thus reducing the risk of horizontal pleiotropy[30,31]. If such cis-pQTLs only influence

transcription or translation of their associated gene, then the risk of horizontal pleiotropy would be

importantly reduced. We searched for the cis-pQTLs for each of 1,216 BMI-driven proteins using

the deCODE study[26]. Following the cis-pQTL search and data harmonization, 334, 335, and 336

proteins were able to be tested in MR for their estimated causal effects on severe COVID-19,

COVID-19 hospitalization, and COVID-19 susceptibility, respectively. Based on a Bonferroni-

adjusted threshold of $P < 1.49 \times 10^{-4}$, MR revealed that a one standard deviation (SD) increase

in genetically predicted NPNT levels was associated with severe COVID-19 (OR = 1.71, 95% CI:

1.45–2.02, $P = 1.63 \times 10^{-10}$) and COVID-19 hospitalization (OR = 1.36, 95% CI: 1.22–1.53, $P =$

4.52×10^{-8}) (**Figure 3** and **Supplementary Table 4 and 5**). Similarly, a one SD increase in

genetically predicted HSD17B14 levels was associated with severe COVID-19 (OR = 1.92, 95%

CI: 1.39–2.65, $P = 6.85 \times 10^{-5}$). Neither of the proteins was convincingly associated with COVID-

19 susceptibility (**Supplementary Table 6**).

To verify the assumption of lack of horizontal pleiotropy, we checked whether the cis-

pQTLs for NPNT and HSD17B14 were associated with any traits or diseases using the

PhenoScanner[32] database at the genome-wide significant threshold of $P = 5 \times 10^{-8}$. In

PhenoScanner, the lead cis-pQTL for NPNT (rs34712979) from the deCODE study was

associated with lung-related traits (**Supplementary Table 7**). However, because NPNT has an

established role as an extracellular matrix protein and fibrosis in the lung[33-35], it is possible that

the NPNT cis-pQTL affects such traits through alteration in NPNT levels, and thus, should not

violate the assumption of no horizontal pleiotropy. Indeed, MR showed that NPNT levels influence

FEV1/FVC (key lung function index used for the definition of chronic obstructive lung disease

(COPD)[36]) and asthma risk (**Supplementary Table 8**). No other cis-pQTL for NPNT or HSD17B14

was associated with any trait or disease, reducing the possibility of horizontal pleiotropy.

Next, to assess potential bias from reverse causation, we tested whether COVID-19

severity influences NPNT levels. Since MR requires that the outcome GWAS is performed in

populations that could be exposed to the exposure of interest, we used a GWAS of plasma protein

levels in 264 individuals during acute infection of SARS-CoV-2 (severe acute respiratory

syndrome coronavirus 2) from the Biobanque Québécoise de la COVID-19 (BQC19)

(**Supplementary Table 1**) (see **Methods**). We did not find evidence that severe COVID-19 and
hospitalization influenced plasma NPNT or HSD17B14 levels (**Supplementary Table 9**).
188
Colocalization analyses investigating whether cis-pQTLs for NPNT and HSD17B14 and
COVID outcomes share the same causal variant
Considering that MR analyses from Step 1 and Step 2 implicated NPNT and HSD17B14 as
candidate proteins mediating the effect of BMI on COVID-19 severity, we performed colocalization
to assess whether the cis-pQTLs for NPNT and HSD17B14 shared the same single causal variant
with severe COVID-19 and hospitalization. The colocalization analyses revealed that NPNT had
a high posterior probability of colocalization with severe COVID-19 and hospitalization (posterior
probability (PP_{shared}) = 100.0% and 99.7%, respectively) (**Figure 4**). Moreover, using Combined
Annotation Dependent Depletion (CADD)-scores[37] as priors, fine-mapping further confirmed that
rs34712979, the lead cis-pQTL for NPNT, was fine-mapped for severe COVID-19 and
hospitalization (**Supplementary Table 10 and 11**). On the other hand, cis-pQTLs for HSD17B14
did not colocalize with either of the outcomes (**Extended Figure 1**), indicating that MR findings
for HSD17B14 may be confounded by LD.
202
Validation analyses using cis-pQTLs for NPNT and HSD17B14 from different cohorts
To validate the findings that plasma NPNT levels were causal for severe COVID-19, we performed
another MR analysis using cis-pQTLs from different cohorts. Additional cis-pQTLs for NPNT and
HSD17B14 were identified based on the FENLAND study by Pietzner *et al*. (n = 10,708)[27] and
the AGES Reykjavik study by Emilsson *et al*. (n = 3,200)[28]. Again, the PhenoScanner database
did not reveal evidence of horizontal pleiotropy for these cis-pQTLs. MR analyses using these
cis-pQTLs estimated a consistent causal effect of NPNT on severe COVID-19 (the AGES
Reykjavik study: OR = 1.25, 95% CI:1.06–1.49, P = 8.26 × 10^{-3}; the FENLAND study: OR = 1.89,
95% CI: 1.04–1.31, P = 7.30× 10^{-3}) and COVID-19 hospitalization (the AGES Reykjavik study,
OR = 1.17, 95% CI:1.06–1.49, P = 8.26 × 10^{-3}; the FENLAND study, OR =1.45, 95% CI: 1.28–
1.66, P = 2.17× 10^{-8}). In contrast, the estimated causal effects of HSD17B14 on these COVID-19
outcomes were not supported (**Supplementary Table 12**). Hence, considering the lack of
replication and colocalization of HSD17B14, we excluded this protein from further analyses.
216
217 **Observational evaluation of the associations between BMI and NPNT, and NPNT and**
218 **severe COVID-19**

Association between BMI and plasma proteins in 2,729 individuals from the INTERVAL study

We compared our MR findings for NPNT with results from the INTERVAL study, which evaluated the associations between BMI and 3,622 plasma protein levels among 2,729 individuals[6]. In the INTERVAL study, a one SD increase in BMI was observationally associated with NPNT (beta = 0.127, 95% CI: 0.088–0.167, P = 4.52 × 10^{-10}), which was directionally consistent with the MR findings.

Association between plasma proteins and risk of COVID-19 in 463 individuals from the BQC19 cohort

Considering the MR analyses (Step 2 MR) used plasma protein levels in a non-infectious state from the deCODE study as the exposures, we observationally assessed whether the plasma levels of NPNT in a non-infectious state was associated with the risk of COVID-19 using logistic regression in 463 non-infectious state individuals from our BQC19 cohort (see **Methods** for a definition of non-infectious state**)**. Logistic regression analysis adjusting for age, sex, and sample collection batch showed that non-infectious plasma levels of NPNT were associated with increased risk of COVID-19 susceptibility (OR = 1.71 95% CI: 1.40–2.12 P = 3.57 x 10^{-7}) (**Supplementary Table 13**). While effect estimates for severe and hospitalized COVID-19 were directionally consistent with COVID-19 susceptibility, the confidence intervals were wide and included the null, perhaps reflecting a small sample size of cases.

Mediation analysis of NPNT on the effect of obesity on severe COVID-19

We then performed a mediation analysis using network MR to understand the extent to which plasma NPNT levels mediate the association between BMI and severe COVID-19. For this purpose, we estimated the effect of BMI on severe COVID-19 mediated by plasma NPNT levels by deploying the product of coefficients method via the two-step MR (**Extended Figure 2**). We first estimated the effect of BMI on plasma NPNT levels and then multiplied this estimate by the effect of plasma NPNT levels on severe COVID-19 outcome adjusted for BMI using multivariable MR (see **Methods** for further details). The ratio of the overall effect mediated by NPNT was calculated by dividing the NPNT-mediated effect estimate by the total effect estimate of BMI on severe COVID-19. We found that plasma NPNT levels mediated 3.7% (95% CI: 0.7–6.7%, P = 1.75×10^{-2}) of the effect of BMI on severe COVID-19.

Colocalization analyses investigating whether cis-pQTL for NPNT and eQTLs and sQTLs of the lung share the same causal variant

Since proteins were measured using SomaScan aptamer–based measurements, the observed differences in NPNT levels measured by the assay may be explained not only by total NPNT levels, but also by levels of particular isoform. Thus, we evaluated whether the cis-pQTL influenced either total RNA expression level or a specific isoform level of NPNT. Given that the lung is a primary target organ in the context of COVID-19 severity, NPNT is highly expressed in the lung, NPNT splice isoforms have previously been implicated as a risk factor for COPD and other lung outcomes[38,39,40], and SNPs influencing a specific isoform level would be a splice QTLs (sQTLs), we performed colocalization analysis of the cis-pQTL with eQTLs and sQTLs for NPNT in lung tissue from GTEx[41].

Colocalization analysis of NPNT pQTL and sQTL within a one-megabase (1-Mb) region (±500 kb) surrounding the lead cis-pQTL (rs34712979) revealed that there was a high probability of the pQTL and sQTL sharing a single causal variant (posterior probability for a shared causal signal (PP_{shared}) = 100.0%). However, this was not true for eQTL (PP_{shared} = 7.4%) (**Figure 5**). Given that the thyroid, lung, and arteries are the top three *NPNT*-expressing tissues according to the GTEx[41], as additional analyses, we performed the same colocalization analyses in thyroid and arteries (aorta, tibial, and coronary) and found that pQTL of NPNT also colocalized with sQTL in these tissues (PP_{shared} = 100.0% for all). It colocalized with eQTL in aorta and tibial artery (PP_{shared} = 100.0% for both) but not in thyroid or coronary artery (PP_{shared} = 11.9% and 5.8%, respectively). Notably, the lead cis-pQTL from the deCODE study, i.e., rs34712979, was also identified by the FENLAND study[27] and has been reported to create a cryptic splice acceptor site, which inserts a three-nucleotide sequence coding a serine residue at the 5'-splice site of exon 2, resulting in perturbations of the alpha-helix motif[38]. Further, this lead cis-pQTL (rs34712979) and another cis-pQTL (rs78213340) from the AGES Reykjavik study—that was not in high LD with rs34712979 (r^2 = 0.234)—were both associated with the same exon-skipping splicing in lung in GTEx (**Supplementary Table 14**). Hence, two different cis-pQTLs of NPNT from three different studies—all using SomaScan—were associated with the same splicing pattern, likely suggesting that the SomaScan assay measures a specific isoform of the NPNT protein.

Collectively, these findings indicate that the NPNT-targeting aptamer of SomaScan could reflect the specific isoform levels and that the specific isoform of NPNT with a serine insertion at the N-terminus influences the effect of NPNT on COVID-19 severity.

Analysis of single-cell RNA-sequencing data in lung autopsy samples of patients who died of COVID-19

To gain insights into the biological role of NPNT in SARS-CoV-2-infected lungs, we explored lung
cell types that significantly expressed *NPNT* gene by analyzing single-cell RNA-sequencing data
from lung autopsy samples (106,792 cells) of 16 patients who died of COVID-19[42] (Single Cell
Portal of the Broad Institute (Accession ID: SCP1052)).

We found that *NPNT* is widely expressed in lung cell types, including epithelial cells (type
1 and type 2 alveolar cells) and fibroblasts, highlighting its role in air exchange and fibrosis.
Furthermore, we conducted a subgroup analysis of SARS-CoV-2-positive and -negative cells and
found that *NPNT* was significantly expressed in SARS-CoV2-positive alveolar cells and fibroblasts
(permutation test *P* < 0.001, see **Methods** for details) (**Extended Figure 3**).

Multivariable MR analyses to assess the effects of body fat and fat-free mass on plasma NPNT levels

Given consistent evidence that BMI influenced NPNT levels, which in turn influence COVID-19
severity, we aimed to identify a way of modulating plasma NPNT levels, by better understanding
if estimated causal effect of BMI on plasma NPNT levels was influenced by fat or fat-free mass in
humans. In Step 1 MR, we showed that increased BMI is estimated to increase plasma levels of
NPNT. However, BMI is a function of height and weight and does not take into account body
compartment: body fat and fat-free mass. Thus, we specifically assessed their independent
effects on plasma NPNT levels. For this, we performed multivariable MR using body fat and fat-
free mass as the exposures and plasma NPNT levels as the outcome (see **Methods**). We found
that a one SD increase in body fat mass was associated with increased levels of NPNT (beta =
0.23, 95% CI: 0.13–0.33, $P = 6.86 \times 10^{-6}$), whereas a one SD increase in body fat-free mass was
associated with decreased levels of NPNT (beta = -0.15, 95% CI: -0.26, -0.04, $P = 5.83 \times 10^{-3}$)
(**Figure 6**). These findings suggest that decreasing body fat mass and increasing fat-free mass
(e.g., thorough appropriate diet and exercise) can reduce plasma NPNT levels and thus reduce
the risk of severe COVID-19.

Discussion

In the present study, we conducted MR analyses and found that NPNT is likely to mediate the

effect of increased BMI on COVID-19 severity. Considering BMI is a highly polygenic trait with

more than 530 associated loci[25] and influences more than 1,200 circulating proteins as shown in

the present and previous studies[6,7], it is remarkable that a single protein accounts for ~4% of the

effect of BMI on severe COVID-19. Additionally, colocalization analyses provided evidence

that the NPNT cis-pQTL is shared with a lung sQTL for NPNT that leads to a splice isoform with

a serine insertion at the N-terminus of NPNT[38]. These results therefore suggest that NPNT

mediates a proportion of BMI's effect on severe COVID-19, and that this effect may be conferred

by alternative splicing of *NPNT*.

NPNT, or nephronectin, is an extracellular matrix protein that controls integrin binding

activity. It is known as a functional ligand of integrin α8/β-1 in kidney development and also

associated with the development, remodeling, and survival of various tissues through the binding

of integrins[43,44]. NPNT has also been implicated in inflammation and autoimmunity[45,46], which may

align with the suggested role of obesity-induced inflammation in COVID-19 severity[47]. In addition,

NPNT is expressed in lung alveolar cells and fibroblasts[48,49], and recent GWASs have identified

that the same NPNT splice variant, rs34712979, is associated with lung function-related traits

(e.g., forced expiratory volume (FEV1), forced vital capacity (FVC), FEV1/FVC) and COPD[39,40].

Our single-cell RNA-sequencing analysis on COVID-19 lung autopsy samples also found that

NPNT was expressed in SARS-CoV-2-infected alveolar cells and fibroblasts, suggesting its role

in air exchange and fibrosis in SARS-CoV-2-affected lungs. These findings collectively suggest

that NPNT alternative splicing, which results in an isoform with a serine insertion in the N-terminus

of the protein, increases the risk of deterioration of the lung function and lung diseases such as

COPD and COVID-19.

This study has both strengths and weaknesses. MR and colocalization analyses robustly

implicated NPNT as a causal mediator of the relationship between BMI and COVID-19 severity.

The robustness of the MR findings was enhanced by the large sample sizes used to derive the

findings. To the best of our knowledge, this is the first study to identify a mediator of BMI on

COVID-19 employing a two-step MR approach, although a previous study used a similar

framework with limited statistical power earlier in the pandemic could not identify a strong protein

signal[50]. Furthermore, our MR findings withstood multiple sensitivity analyses and were supported

by colocalization, fine-mapping, observational validation using the independent cohorts, and

RNA-sequencing studies in COVID-19 lung samples. Intriguingly, multivariable MR showed that

plasma NPNT levels were increased by body fat mass but decreased by fat-free mass, indicating

that the effect of BMI on plasma NPNT levels was driven by body fat mass and partially

counteracted by fat-free mass. These findings not only suggest that NPNT can be a potential

target of pharmaceutical intervention in obese individuals to prevent severe COVID-19 but also

highlight one of the possible mechanisms by which appropriate diet and exercise can confer risk

reduction of COVID-19 severity through the reduction in plasma NPNT levels.

This study also has important limitations. First, MR and colocalization analyses were

restricted to individuals of European ancestry to maximize statistical power, and whether NPNT

mediates the effect of BMI on severe COVID-19 in populations of non-European ancestries

requires further investigation. Second, because there were no genome-wide significant genetic

instrumental variables for BMI in the 1-Mb region around the cis-region of NPNT (1-Mb around

the transcription start site), we cannot pinpoint a single genetic variant that directly links BMI to

NPNT. Hence, the effect of BMI on NPNT is likely mediated by a combination of multiple trans-

effects, which was also indicated by the scatter plot in Step 1 MR analysis for NPNT. However,

this is not surprising considering BMI is a highly polygenic, complex trait, and multiple pathways

could confer the effect of BMI on other diseases[51]. Third, we do not know the molecular

mechanism by which BMI influences the splice isoform. Previous studies have suggested that

obesity is associated with alternative splicing[52-54] and extracellular matrix protein remodeling[55],

which may align with our findings. However, further investigation is required to clarify the specific

molecular mechanisms involved. Lastly, we do not rule out the possibility that total levels of NPNT

(all isoforms) measured by NPNT-targeting aptamer are mediating the effect of obesity on COVID-

19 severity. However, given the evidence provided by the MR, colocalization, and fine-mapping

as well as a biological understanding of lead cis-pQTL (i.e., the variant causes alternative splicing

resulting in perturbations of the alpha-helix motif in the lung), it is likely that the specific isoform

measured by the aptamer is driving the effect. Nevertheless, isoform-specific measurements (e.g.,

mass spectrometry) will be required to confirm these findings.

In conclusion, we integrated multiple lines of MR analyses and genetic colocalization

evidence to identify NPNT as a mediator of the effect of BMI on severe COVID-19. We also

disentangled the effect of BMI on NPNT and showed that NPNT is increased by body fat mass

and decreased by body fat-free mass, highlighting the effect of obesity on COVID-19 severity

through NPNT is conferred by body fat mass. These findings provide actionable insights into how

obesity influences COVID-19 severity.

Online Methods

Step 1: Identifying the effects of BMI on plasma proteins

Two-sample MR

BMI GWAS: We used the BMI GWAS meta-analysis with the largest sample size, comprising

693,529 European ancestry individuals from the GIANT consortium and UK Biobank[25]. The details

of the consortium are provided in **Supplementary Table 1**.

Proteomic GWAS: For GWAS of plasma protein levels, we used the largest proteomic GWAS

available[26], which measured 4907 proteins in 35,559 individuals of European ancestry using the

SomaLogic SomaScan assay v4 (SOMAscan, SomaLogic, Boulder, Colorado, USA).

Two-sample MR: The effect of BMI on plasma protein levels was assessed using the inverse

variance weighted method in TwoSampleMR v.0.5.6[56] (https://mrcieu.github.io/TwoSampleMR/).

The instrumental variables for the exposure were defined as genome-wide significant and

independent single nucleotide polymorphisms (SNPs) ($P < 5 \times 10^{-8}$) that were not in LD with other

SNPs ($r^2 < 0.001$, with a clumping window of 1 Mb). SNPs in the human major histocompatibility

complex (MHC) region at chromosome 6: 28,477,797–33,448,354 (GRCh38) were excluded

considering its complex LD structure. We used PLINK v1.9[57]

(http://pngu.mgh.harvard.edu/purcell/plink/) to obtain instrumental variables by clumping SNPs

using the 1000 Genomes Project European reference panel[58] and applying an LD threshold of r^2

< 0.001. The genome-wide significant independent SNPs with the lowest P-value were selected

from each LD block. Data harmonization was performed using default settings of TwoSampleMR,

including removal of palindromic SNPs that have minor allele frequency above 0.42. A Bonferroni

correction was used to set a statistical significance threshold, by dividing 0.05 by the number of

proteins ($P = 1.0 \times 10^{-5}$ (0.05/4907)). We note that this correction is overly-conservative since

many proteins are non-independent. For evaluating horizontal pleiotropy, we used the MR-Egger

intercept test; where horizontal pleiotropy was considered to be present when the MR-Egger

intercept differed from the null ($P < 0.05$). For NPNT and HSD17B14, we used MR-Egger,

weighted median, and weighted mode methods as additional sensitivity analyses to evaluate

directional consistency of beta coefficients with the inverse variance weighted method.

For reverse MR, in which the effects of plasma protein levels on BMI were assessed, we

used the cis-pQTLs from the deCODE study as the exposure and BMI GWAS as the outcome,

deploying the inverse variance weighted method or Wald ratio method when only one SNP was

available as an instrumental variable. After the cis-pQTL search using data from the deCODE

study and data harmonization, 332 proteins were tested in MR for their estimated reverse effects.

Results with $P = 1.51 \times 10^{-4}$ (0.05/332; Bonferroni correction) were considered statistically

significant. We used BMI GWAS from the UK Biobank (not the meta-analysis GWAS) because

multiple variants, including cis-pQTL for NPNT from the deCODE study (rs34712979), were

dropped during the stringent quality control process of the meta-analysis (e.g., rs34712979 was

not present in the GIANT GWAS and thus dropped during the meta-analysis process).

Step 2: Identifying the effects of BMI-driven proteins on COVID-19 severity

Two-sample MR

Cis-pQTL GWAS: We identified cis-pQTLs from the GWAS of 4,907 proteins in 35,559

individuals of European ancestry from the deCODE study[26]. Cis-pQTLs were defined as pQTLs

that were located within 1-Mb (± 500 kb) of the transcription start site of the protein-coding gene.

COVID-19 outcome GWAS: For COVID-19 outcomes, we used a GWAS meta-analysis from the

COVID-19 Host Genetics Initiatives data release 7 (https://www.covid19hg.org/). The outcomes

included severe COVID-19 (13,769 cases and 1,072,442 controls), COVID-19 hospitalization

(32,519 cases and 2,062,805 controls), and COVID-19 susceptibility (1,22,616 cases and

2,475,240 controls). Severe COVID-19 was defined as a requirement for respiratory support

among hospitalized individuals with laboratory-confirmed SARS-CoV-2 infection or death due to

COVID-19. COVID-19 hospitalization was defined as a laboratory-confirmed SARS-CoV-2

infection that required hospitalization. COVID-19 susceptibility was defined as SARS-CoV-2

infection determined by laboratory testing (nucleic acid amplification or serology tests), physicians'

diagnosis on electrical medical records, or self-report questionnaires.

Two-sample MR: Using the data above, we undertook two-sample MR for the effects of plasma

protein levels on three COVID-19 outcomes. Results with a $P < 1.49 \times 10^{-4}$ (0.05/336; Bonferroni

correction with the number of proteins tested in the Step 2 MR) were considered statistically

significant. Given that certain proteins had only one genetic instrumental variable, for which the

MR-Egger intercept test cannot be performed, we used the PhenoScanner database to test

whether variants had potential pleiotropic associations with other diseases or traits. Associations

with $P < 5 \times 10^{-8}$ were considered statistically significant.

We assessed reverse causation, wherein the effect of COVID-19 may influence plasma
protein levels, using data hosted on a COVID-19 biobank (the BQC19 cohort) because MR
requires the outcome GWAS to be performed in populations potentially exposed to the exposure
of interest. Toward this, we used GWAS of plasma protein levels in 487 SARS-CoV-2-infected
individuals from the BQC19 cohort (described below). Results with $P < 1.49 \times 10^{-4}$ (0.05/336;
Bonferroni correction with the number of BMI-driven proteins evaluated) were considered
statistically significant.

The BQC-19 cohort: BQC19 is a province-wide biobank that provides global access to important
biological and clinical data from patients with COVID-19 as well as control subjects in Québec,
Canada (https://www.bqc19.ca/). Blood samples were collected in acid citrate dextrose (ACD)
tubes from 264 SARS-CoV-2 infectious and 463 non-infectious patients of European ancestry
(see below for the detailed definition of infectious or non-infectious state). The samples underwent
proteomic profiling on the SomaScan v4 assay. Up to 5,284 aptamers were measured for these
samples. After removing any aptamers that represented non-human proteins or controls, we
retained 4,907 aptamers for analysis, consistent with the deCODE study[26]. SomaLogic performed
normalization and calibration steps to remove systematic biases, which are detailed in their
technical note (https://www.mcgill.ca/genepi/files/genepi/bqc19_jgh_prt_tech_note_0.pdf). Blood
samples were sent to SomaLogic at two-time points during the pandemic, providing two batches
of proteomic measurements. For quality control, protein levels were natural log-transformed and
then batch corrected using the ComBat function implemented in the sva R package[59], which uses
an empirical Bayesian framework to perform batch effect removal.

Definition of SARS-CoV-2 infectious or non-infectious state in the BQC-19 cohort: We
defined infectious and non-infectious state as follows (all date ranges are inclusive): infectious
samples were defined as blood samples collected from individuals who tested positive for SARS-
CoV-2 test from 7 days before and up to and including 14 days after the first date of SARS-CoV-
2-associated symptoms. Non-infectious samples were defined as those meeting either of the
following three criteria: (1) Samples were collected from individuals who tested negative for
SARS-CoV-2; (2) samples were collected within 31 days after but 90 days before the first date of
symptoms from patients whose positive SARS-CoV-2 test was confirmed within 7 days from the
first symptom onset; (3) samples were collected at least 15 days before or at least 31 days after
the positive SARS-CoV-2 test from patients whose positive SARS-CoV-2 test was confirmed at

least 7 days before or after the first symptom onset. Further details can be found at
https://github.com/richardslab/BQC19_phenotypeQC/blob/main/src/COVID-19%20Omics.svg.
489
GWAS of plasma protein levels in SARS-CoV-2 infectious individuals from the BQC19
cohort: GWAS of plasma protein levels in SARS-CoV-2 infectious individuals of European
ancestry were performed using fastGWA from the GCTA package
(https://yanglab.westlake.edu.cn/software/gcta/)[60] after rank-based inverse normal
transformation of protein levels and adjusting for the first 10 principal components, batch, age,
and sex as well as restricting genetic variants to those with MAF > 0.05. Genotyping was
performed with Axiom Precision Medicine genotyping array. Genotypic imputation was performed
using the TOPMed Imputation Reference panel[61] while retaining only SNPs with MAF > 0.01 and
INFO score > 0.6.
499

Colocalization analysis of cis-pQTL for NPNT and HSD17B14 and COVID outcomes
To identify potential bias caused by confounding owing to LD, we performed colocalization to
evaluate whether cis-pQTLs shared a single causal variant between the three COVID-19
outcomes for the causal proteins and NPNT or HSD17B14. We used the coloc R package v5.1.0[62]
(https://chr1swallace.github.io/coloc/) to evaluate all SNPs in the 1-Mb region (± 500 kb) around
the top cis-pQTL for the NPNT (defined as the cis-pQTL with the smallest P-value). The posterior
probability of hypothesis 4 or PP_{shared} (two traits sharing a single causal variant) > 0.8 was
considered to indicate strong evidence of colocalization. Colocalization analyses were conducted
using the coloc R package v5.1.0[62], using default priors of $p1 = p2 = 10^{-4}$ and $p12 = 10^{-5}$ where
$p1$ is a prior probability that only trait 1 has a genetic association in the region, $p2$ is a prior
probability that only trait 2 has a genetic association in the region, and $p12$ is a prior probability
that both trait 1 and trait 2 share the same genetic association in the region.
512

Fine-mapping of the NPNT region for severe COVID-19 and hospitalization GWASs
The COVID-19 Host Genetics Initiatives release 7 data for those of European ancestry with
severe COVID-19 and hospitalization were inputted into FINEMAP v1.4[63]
(http://www.christianbenner.com/) using default options. We assumed a maximum of one causal
SNP given a single GWAS significant SNP in the NPNT region. Summary statistics were filtered
for SNPs present in European ancestry, as done by Huffman et al[64]. We set prior probabilities
using scaled CADD-PHRED scores[37] (https://cadd.gs.washington.edu/). The scaled CADD-
PHRED scores were normalized so their sum equaled one. The variance of effect size prior was

set such that the maximum odds ratio a variant can have with 95% probability is two, then scaled

using the case-control ratio as described previously[64].

Validation analyses using cis-pQTL for NPNT and HSD17B14 from different cohorts

We also obtained cis-pQTLs and their beta estimates for plasma protein levels of NPNT and

HSD17B14 from the FENLAND study and AGES Reykjavik study. We repeated the two-sample

MR using these cis-pQTLs as instrumental variables and the three COVID-19 outcomes as

described above.

Observational evaluation of associations between BMI and NPNT, and NPNT and COVID-

19

Observational evaluation of associations between BMI and plasma NPNT levels in 2737

individuals from the INTERVAL study

The INTERVAL study was a prospective cohort study conducted in England. The study recruited

~50,000 participants of mostly European ancestry without a self-reported history of major disease.

The recruitment took place between 2012 and 2014, before the COVID-19 pandemic. The study

measured 3622 plasma protein levels in 2737 individuals using the SomaScan assay. The study

performed a linear regression to evaluate associations between BMI and plasma protein levels

adjusting for age and sex. The derived beta estimates represented normalized SD-unit difference

in each protein level per one SD (4.8 kg/m^2) increase in BMI. Further details of the study have

been described in detail previously[6].

Observational evaluation of associations between plasma NPNT levels in the non-

infectious state and COVID-19 severity in 463 individuals from the BQC19 cohort

Given that the MR analyses used plasma protein levels in a non-infectious state as the exposures,

we observationally assessed an association between plasma NPNT and risk of COVID-19

outcomes in the BQC19 cohort. Non-infectious individuals were defined above. We defined the

COVID-19 outcomes in accordance with those for the GWAS from COVID-19 Host Genetics

Initiative. (I) Severe COVID-19: cases were defined as laboratory-confirmed SARS-CoV-2

infection by PCR or serology testing combined with the requirement for respiratory support or

death. Controls were defined as those who did not meet the criteria. (II) Hospitalization: cases

were defined as those who were hospitalized due to COVID-19-related symptoms. Those who

did not fulfill the case definition were defined as controls. (III) Susceptibility: we define cases as

those with SARS-CoV-2 infection confirmed in the laboratory testing. Those who tested negative

were used as controls.

We performed logistic regression analysis using one of the COVID-19 outcomes as the

dependent variable and standardized plasma NPNT levels as the independent variable while

adjusting for sex, age, and batch number.

Mediation analysis of NPNT on the effect of obesity on COVID-19 severity

We undertook mediation analysis to calculate the proportion of BMI's effect on severe COVID-19

mediated by NPNT using network MR (**Extended Figure 2**). We used the product of coefficient

method to estimate the NPNT-mediated effect (i.e., the effect of BMI on severe COVID-19 that

was accounted for by NPNT): First, we estimated the effect of BMI on NPNT, then multiplied this

with the effect of NPNT on severe COVID-19. Subsequently, the proportion of the total effect of

BMI on COVID-19 mediated by NPNT was estimated by dividing the NPNT-mediated effect ($\beta_{\text{NPNT-}}$

$_{\text{to-severe COVID-19}}$) by the total effect ($\beta_{\text{BMI-to-NPNT}}$), as described previously[65,66].

For this mediation analysis, we used the BMI GWAS from the UK Biobank

(https://gwas.mrcieu.ac.uk/datasets/ukb-b-19953/), which was less powered than the meta-

analysis of GIANT consortium and UK Biobank (sample size: 681,275 vs. 456,426, respectively).

This was because the lead cis-pQTL (rs34712979) was present in UK Biobank but absent in the

GIANT GWAS and their meta-analysis GWAS. Given that multivariable MR requires at least one

genetic variant shared among the exposures, multivariable MR using BMI and NPNT as the

exposures was possible only with the BMI GWAS from UK Biobank, which contains the two cis-

pQTLs from the deCODE study, where rs34712979 is the lead cis-pQTL.

Follow-up analyses for NPNT

Colocalization analysis of cis-pQTL with eQTL and sQTL from GTEx

sQTL and eQTL GWAS: We used sQTL and eQTL GWASs of the lung as well as those of thyroid

and arteries (i.e., the top three *NPNT*-expressing tissues) in European-ancestry individuals from

the GTEx Portal V8 dataset[41] (https://gtexportal.org/).

Colocalization analyses: To evaluate whether cis-pQTL is more affected by sQTL, rather than

total expression, we also undertook colocalization of the cis-pQTL with eQTLs and sQTLs of

NPNT using the GTEx V8 dataset. Colocalization analyses were performed in the 1 Mb region

around the cis-pQTL for NPNT (rs34712979) using the coloc v5.1.0[62] with default priors of $p1 =$

$p2 = 10^{-4}$ and $p12 = 10^{-5}$ where $p1$ is a prior probability that only trait 1 has a genetic association

in the region, $p2$ is a prior probability that only trait 2 has a genetic association in the region, and

$p12$ is a prior probability that both trait 1 and trait 2 share the same genetic association in the

region. $PP_{shared} > 0.8$ was considered to indicate strong evidence of colocalization. We also

evaluated whether the lead cis-pQTL from the deCODE study (rs34712979), the FENLAND study

(rs34712979), and AGES Reykjavik study (rs78213340) were associated with the same splice

pattern in the lung using GTEx. For eQTL and sQTL, we considered associations with $P < 1 \times 10^{-7}$

statistically significant, as did the deCODE study[26].

Single-cell RNA-sequencing data analysis

To understand the *NPNT* expression pattern in the lungs of SARS-CoV-2 infected individuals, we

obtained single-cell transcriptomic data of SARS-CoV-2-infected lungs by Delorey *et al*[42]. from

the Single Cell Portal of the Broad Institute (https://singlecell.broadinstitute.org/single_cell/)

(Accession ID: SCP1052). The data contained 106,792 single cells from the lungs of 16 autopsy

donors aged 30 to older than 89 years who died due to COVID-19. For data processing, briefly,

the study aligned FASTQ files to the reference genome of Homo sapiens, and SARS-CoV-2 and

ambient RNA were removed using CellBender. Quality control was performed under the Cumulus

single-cell analysis workflow. Cell types were assigned using an automatic prediction approach,

followed by manually curating marker genes and gene signatures[42].

For NPNT expression analysis, we reanalyzed the data focusing on NPNT expression

status. We analyzed the gene expression matrix and the associated metadata using R v4.1.2

and Seurat R package v4.1.1[67] (https://satijalab.org/seurat/). For visualization, NPNT

expression levels were represented on a log-transcript per 10 thousand + 1, i.e., log (TP10K+1)

scale. To cluster the cells, we adopted the clustering annotation from the original study[42]. To

test whether *NPNT* expression was enriched in a cell type, we calculated the proportion of

NPNT-expression cells in this cell type. Subsequently, we permuted the cell type labels 1,000

times, and obtained the frequency (permutation p-value) of the same cell type containing the

same or a larger proportion of *NPNT*-expression cells. Additionally, we compared the *NPNT*

expression level between a target cell type and the other cell types using Wilcoxon rank-sum

test. This enrichment analysis was performed separately in SARS-CoV-2-infected and

uninfected cells.

Multivariable MR analysis using body fat and fat-free mass

Body fat and fat-free mass GWAS: We obtained GWAS of body fat and fat-free mass from UK Biobank using the IEU OpenGWAS project (https://gwas.mrcieu.ac.uk/). Accession ID for each GWAS was 'ukb-b-19393' and 'ukb-b-13354', respectively.

NPNT GWAS: For GWAS of plasma NPNT levels, we used the same GWAS from the deCODE study[26] as the one used in Step 1 MR, which measured plasma NPNT levels in 35,559 individuals of European ancestry by using the SomaLogic SomaScan assay v4.

Multivariable MR: For instrumental variables, we identified genome-wide significant and independent SNPs for body fat and fat-free mass using the same criteria as in the Step1 MR (i.e., $P < 5 \times 10^{-8}$ for significance and $r^2 < 0.001$ with a clumping window of 1 Mb for independence). SNPs in the MHC region were excluded. After data harmonization, we undertook multivariable MR with the inverse variance weighted method using body fat and fat-free mass as the exposures and plasma NPNT levels as the outcome. Results with $P < 0.025$ (0.05/2; Bonferroni correction) were considered statistically significant. LD clumping was performed using PLINK v1.9[57]. Data harmonization and multivariable MR were performed using TwoSampleMR v.0.5.6[56].

Ethical approval

For summary-level data, all contributing cohorts obtained ethical approval from their intuitional ethics review boards. The contributing cohorts include: UK Biobank, GIANT consortium, deCODE study, FENLAND study, AGES Reykjavik study, INTERVAL study, COVID-19 Host Genetics Initiative, and BQC19. For individual-level data in BQC19, BQC19 received ethical approval from the Jewish General Hospital research ethics board (2020-2137) and the Centre hospitalier de l'Université de Montréal institutional ethics board (MP-02-2020-8929, 19.389).

Data availability

·GWAS summary statistics for each trait are available as follows:

BMI (https://portals.broadinstitute.org/collaboration/giant/),

Plasma proteome from the deCODE study (https://www.decode.com/summarydata/),

COVID-19 outcomes (https://www.covid19hg.org/results/r7/),

GTEx Portal V8 (https://gtexportal.org/home/datasets/).

Plasma proteome from BQC19 (https://www.mcgill.ca/genepi/mcg-covid-19-biobank).

Access to the data of BQC19 can be obtained upon approval of requests.

·Cis-pQTLs of each study are available in the corresponding publications' supplementary materials[26-28].

Body fat and fat-free mass GWASs are available at IEU OpenGWAS project with Accession ID of ukb-b-19393 and ukb-b-13354, respectively (https://gwas.mrcieu.ac.uk/).

·Single-cell RNA-sequencing data of COVID-19 lung autopsy samples are available at the Single Cell Portal under the Accession ID of SCP1052 (https://singlecell.broadinstitute.org/single_cell/).

·CADD-scores v.1.6 can be accessed at https://cadd.gs.washington.edu/score.

·Genotype data from 1000G genomes project is available at https://www.internationalgenome.org/data.

Acknowledgments

We thank the COVID-19 Host Genetics Initiative for providing the latest summary statistics for COVID-19 outcomes. The Richards research group is supported by the Canadian Institutes of Health Research (CIHR: 365825; 409511, 100558, 169303), the McGill Interdisciplinary Initiative in Infection and Immunity (MI4), the Lady Davis Institute of the Jewish General Hospital, the Jewish General Hospital Foundation, the Canadian Foundation for Innovation, the NIH Foundation, Cancer Research UK, Genome Québec, the Public Health Agency of Canada, McGill University, Cancer Research UK [grant number C18281/A29019] and the Fonds de Recherche Québec Santé (FRQS). JBR is supported by an FRQS Mérite Clinical Research Scholarship. Support from Calcul Québec and Compute Canada is acknowledged. TwinsUK is funded by the Welcome Trust, Medical Research Council, European Union, the National Institute for Health Research (NIHR)-funded BioResource, Clinical Research Facility and Biomedical Research Centre based at Guy's and St Thomas' NHS Foundation Trust in partnership with King's College London. S.Y. is supported by the Japan Society for the Promotion of Science. T.L. has been supported by a Vanier Canada Graduate Scholarship, an FRQS doctoral training fellowship, and a McGill University Faculty of Medicine Studentship. These funding agencies above had no role in the design, implementation, or interpretation of this study.

Author contributions

Conception and design: S.Y. and J.B.R. Methodology: S.Y., T.L., and J.B.R. Data analysis: S.Y., T.L., J.D.S.W., C.Y.S., and J.B.R. Visualization: S.Y. and T.L. Writing – original draft: S.Y. Writing – Review and editing: S.Y., G.B.L., T.L., J.D.S.W., C.Y.S., T.N., D.M., Y.C., K.L., M.H., Z.A., S.L., N.D., C.D., M.V., C.T., X.X., M.B., F.S., L.L., H.M.M., M.A., J.A., V.M., N.J.T., H.Z., S.Z., V.F., Y.F., and J.B.R.

Disclosures

J.B.R. has served as an advisor to GlaxoSmithKline and Deerfield Capital. J.B.R.'s institution has received investigator-initiated grant funding from Eli Lilly, GlaxoSmithKline, and Biogen for projects unrelated to this research. He is the CEO of 5 Prime Sciences (www.5primesciences.com), which provides research services for biotech, pharma, and venture capital companies for projects unrelated to this research. T.L., V.F., and Y.F are employees of 5 Prime Sciences.

References

Johns Hopkins University. COVID-19 global map. https://coronavirus.jhu.edu/map.html. Accessed on June 3, 2022.

COVID-19 Host Genetics Initiative. Mapping the human genetic architecture of COVID-19. *Nature* **600**, 472-477 (2021).

Stefan, N., Birkenfeld, A. L., Schulze, M. B. & Ludwig, D. S. Obesity and impaired metabolic health in patients with COVID-19. *Nat Rev Endocrinol* **16**, 341-342 (2020).

Foulkes, A. S. *et al.* Understanding the link between obesity and severe COVID-19 outcomes: Causal mediation by systemic inflammatory response. *J Clin Endocrinol Metab*, e698–e707, https://doi.org/10.1210/clinem/dgab629 (2022).

Zickler, M. *et al.* Replication of SARS-CoV-2 in adipose tissue determines organ and systemic lipid metabolism in hamsters and humans. *Cell Metab* **34**, 1-2 (2022).

Goudswaard, L. J. *et al.* Effects of adiposity on the human plasma proteome: observational and Mendelian randomisation estimates. *Int J Obes (Lond)* **45**, 2221-2229 (2021).

Zaghlool, S. B. *et al.* Revealing the role of the human blood plasma proteome in obesity using genetic drivers. *Nat Commun* **12**, 1279, https://doi.org/10.1038/s41467-021-21542-4 (2021).

Filbin, M. R. *et al.* Longitudinal proteomic analysis of severe COVID-19 reveals survival-associated signatures, tissue-specific cell death, and cell-cell interactions. *Cell Rep Med* **2**, 100287, https://doi.org/10.1016/j.xcrm.2021.100287 (2021).

Skrivankova, V. W. *et al.* Strengthening the Reporting of Observational Studies in Epidemiology Using Mendelian Randomization. *JAMA* **326**, 1614 (2021).

Skrivankova, V. W. *et al.* Strengthening the reporting of observational studies in epidemiology using mendelian randomisation (STROBE-MR): explanation and elaboration. *BMJ* **375**, n2233, https://doi.org/10.1136/bmj.n2233 (2021).

Ponsford, M. J. *et al.* Cardiometabolic Traits, Sepsis, and Severe COVID-19: A Mendelian Randomization Investigation. *Circulation* **142**, 1791-1793, (2020).

Luo, S., Liang, Y., Wong, T. H. T., Schooling, C. M. & Au Yeung, S. L. Identifying factors contributing to increased susceptibility to COVID-19 risk: a systematic review of Mendelian randomization studies. *Int J Epidemiol,* dyac076, https://doi.org/10.1093/ije/dyac076 (2022).

Zhou, S. *et al.* A Neanderthal OAS1 isoform protects individuals of European ancestry against COVID-19 susceptibility and severity. *Nat Med* **27**, 659-667, (2021).

14   Gaziano, L. *et al.* Actionable druggable genome-wide Mendelian randomization identifies
repurposing opportunities for COVID-19. *Nat Med* **27**, 668-676, (2021).
15   Bovijn, J., Lindgren, C. M. & Holmes, M. V. Genetic variants mimicking therapeutic
inhibition of IL-6 receptor signaling and risk of COVID-19. *Lancet Rheumatol* **2**, e658-e659,
https://doi.org/10.1016/s2665-9913(20)30345-3 (2020).
16   Pietzner, M. *et al.* ELF5 is a respiratory epithelial cell-specific risk gene for severe COVID-
19. *medRxiv*, https://doi.org/10.1101/2022.01.17.22269283 (2022).
17   Klaric, L. *et al.* Mendelian randomisation identifies alternative splicing of the FAS death
receptor   as   a   mediator   of   severe   COVID-19.   *medRxiv*,
https://doi.org/10.1101/2021.04.01.21254789 (2021).
18   Niemi, M. E. K., Daly, M. J. & Ganna, A. The human genetic epidemiology of COVID-19.
Nat Rev Genet, https://doi.org/10.1038/s41576-022-00478-5 (2022).
19   Recovery Collaborative Group. Tocilizumab in patients admitted to hospital with COVID-
19 (RECOVERY): a randomised, controlled, open-label, platform trial. *Lancet* **397**, 1637-
1645 (2021).
20   Holmes, M. V., Richardson, T. G., Ference, B. A., Davies, N. M. & Davey Smith, G.
Integrating genomics with biomarkers and therapeutic targets to invigorate cardiovascular
drug development. *Nat Rev Cardiol* **18**, 435-453 (2021).
21   Manousaki, D., Mokry, L. E., Ross, S., Goltzman, D. & Richards, J. B. Mendelian
randomization studies do not support a role for vitamin D in coronary artery disease. *Circ.*
Cardiovasc Genet **9**, 349-356 (2016).
22   Jiang, X. *et al.* Circulating vitamin D concentrations and risk of breast and prostate cancer:
a Mendelian randomization study. *Int J Epidemiol* **48**, 1416-1424 (2019).
23   Meng, X. *et al.* Phenome-wide Mendelian-randomization study of genetically determined
vitamin D on multiple health outcomes using the UK Biobank study. *Int J Epidemiol* **48**,
1425-1434 (2019).
24   Manson, J. E. *et al.* Vitamin D Supplements and Prevention of Cancer and Cardiovascular
Disease. *N Engl J Med* **380**, 33-44 (2019).
25   Yengo, L. *et al.* Meta-analysis of genome-wide association studies for height and body
mass index in ~700000 individuals of European ancestry. *Human Mol Genet* **27**, 3641-
3649 (2018).
26   Ferkingstad, E. *et al.* DECODE: Large-scale integration of the plasma proteome with
genetics and disease. *Nat Genet* **53**, 1712-1721 (2021).
27   Pietzner, M. *et al.* Synergistic insights into human health from aptamer- and antibody-
based proteomic profiling. *Nat Commun* **12**, 6822, https://doi.org/10.1038/s41467-021-
27164-0 (2021).
28   Emilsson, V. *et al.* Co-regulatory networks of human serum proteins link genetics to
disease. *Science* **361**, 769-773 (2018).
29   Bowden, J., Davey Smith, G. & Burgess, S. Mendelian randomization with invalid
instruments: effect estimation and bias detection through Egger regression. *Int J*
Epidemiol **44**, 512-525 (2015).
30   Swerdlow, D. I. *et al.* Selecting instruments for Mendelian randomization in the wake of
genome-wide association studies. *Int J Epidemiol* **45**, 1600-1616 (2016).

31   Zhang, J. *et al.* Plasma proteome analyses in individuals of European and African ancestry
identify cis-pQTLs and models for proteome-wide association studies. *Nat Genet*,
https://doi.org/10.1038/s41588-022-01051-w (2022).
32   Staley, J. R. *et al.* PhenoScanner: a database of human genotype-phenotype associations.
Bioinformatics **32**, 3207-3209 (2016).
33   Tsukui, T. *et al.* Collagen-producing lung cell atlas identifies multiple subsets with distinct
localization and relevance to fibrosis. *Nat Commun* **11**, 1920,
https://doi.org/10.1038/s41467-020-15647-5 (2020).
34   Xie, T. *et al.* Single-Cell Deconvolution of Fibroblast Heterogeneity in Mouse Pulmonary
Fibrosis. *Cell Rep* **22**, 3625-3640 (2018).
35   Obeidat, M. e. *et al.* Molecular mechanisms underlying variations in lung function: a
systems genetics analysis. *Lancet Respir Med* **3**, 782-795 (2015).
36   Bhatt, S. P. *et al.* Discriminative Accuracy of FEV1:FVC Thresholds for COPD-Related
Hospitalization and Mortality. *JAMA* **321**, 2438-2447,
https://doi.org/10.1001/jama.2019.7233 (2019).
37   Kircher, M. *et al.* A general framework for estimating the relative pathogenicity of human
genetic variants. *Nat Genet* **46**, 310-315 (2014).
38   Saferali, A. *et al.* Characterization of a COPD-associated NPNT functional splicing genetic
variant in human lung tissue via long-read sequencing. *medRxiv*,
https://doi.org/10.1101/2020.10.20.20203927 (2020).
39   Shrine, N. *et al.* New genetic signals for lung function highlight pathways and chronic
obstructive pulmonary disease associations across multiple ancestries. *Nat Genet* **51**,
481-493, https://doi.org/10.1038/s41588-018-0321-7 (2019).
40   Sakornsakolpat, P. *et al.* Genetic landscape of chronic obstructive pulmonary disease
identifies heterogeneous cell-type and phenotype associations. *Nat Genet* **51**, 494-505
(2019).
41   GTEx Consortium. The GTEx Consortium atlas of genetic regulatoryeffects across human
tissues. *Science* **369**, 1318-1330 (2020).
42   Delorey, T. M. *et al.* COVID-19 tissue atlases reveal SARS-CoV-2 pathology and cellular
targets. *Nature* **595**, 107-113 (2021).
43   Brandenberger, R. *et al.* Identification and characterization of a novel extracellular matrix
protein nephronectin that is associated with integrin alpha8beta1 in the embryonic kidney.
J Cell Biol **154**, 447-458 (2001).
44   Morimura, N. *et al.* Molecular cloning of POEM: a novel adhesion molecule that interacts
with alpha8beta1 integrin. *J Biol Chem* **276**, 42172-42181 (2001).
45   Inagaki, F. F. *et al.* Nephronectin is upregulated in acute and chronic hepatitis and
aggravates liver injury by recruiting CD4 positive cells. *Biochem Biophys Res Commun*
430, 751-756 (2013).
46   Kon, S., Honda, M., Ishikawa, K., Maeda, M. & Segawa, T. Antibodies against
nephronectin ameliorate anti-type II collagen-induced arthritis in mice. *FEBS Open Bio* **10**,
107-117 (2020).
47   O'Rourke, R. W. & Lumeng, C. N. Pathways to severe COVID-19 for people with obesity.
Obesity (Silver Spring) **29**, 645-653 (2021).

48   Strunz, M. *et al.* Alveolar regeneration through a Krt8+ transitional stem cell state that persists in human lung fibrosis. *Nat Commun* **11**, 3559, https://doi.org/10.1038/s41467-020-17358-3 (2020).

49   Xie, T. *et al.* Mesenchymal growth hormone receptor deficiency leads to failure of alveolar progenitor cell function and severe pulmonary fibrosis. *Sci Adv* **7**, eabg6005, https://doi.org/10.1126/sciadv.abg6005 (2021).

50   Richardson, T. G., Fang, S., Mitchell, R. E., Holmes, M. V. & Davey Smith, G. Evaluating the effects of cardiometabolic exposures on circulating proteins which may contribute to severe SARS-CoV-2. *EBioMedicine* **64**, 103228, https://doi.org/10.1016/j.ebiom.2021.103228 (2021).

51   Locke, A. E. *et al.* Genetic studies of body mass index yield new insights for obesity biology. *Nature* **518**, 197-206, https://doi.org/10.1038/nature14177 (2015).

52   Pihlajamaki, J. *et al.* Expression of the splicing factor gene SFRS10 is reduced in human obesity and contributes to enhanced lipogenesis. *Cell Metab* **14**, 208-218 (2011).

53   Zhao, X. *et al.* FTO-dependent demethylation of N6-methyladenosine regulates mRNA splicing and is required for adipogenesis. *Cell Res* **24**, 1403-1419 (2014).

54   Roundtree, I. A., Evans, M. E., Pan, T. & He, C. Dynamic RNA modifications in gene expression regulation. *Cell* **169**, 1187-1200 (2017).

55   Kim, M., Lee, C. & Park, J. Extracellular matrix remodeling facilitates obesity-associated cancer progression. *Trends Cell Biol* https://doi.org/10.1016/j.tcb.2022.02.008 (2022).

56   Hemani, G. *et al.* The MR-Base platform supports systematic causal inference across the human phenome. *eLife* **7**, e34408, https://doi.org/10.7554/elife.34408 (2018).

57   Purcell, S. *et al.* PLINK: a tool set for whole-genome association and population-based linkage analyses. *Am J Hum Genet* **81**, 559-575 (2007).

58   Genomes Project, C. *et al.* A global reference for human genetic variation. *Nature* **526**, 68-74 (2015).

59   Leek, J. T., Johnson, W. E., Parker, H. S., Jaffe, A. E. & Storey, J. D. The sva package for removing batch effects and other unwanted variation in high-throughput experiments. *Bioinformatics* **28**, 882-883 (2012).

60   Jiang, L. *et al.* A resource-efficient tool for mixed model association analysis of large-scale data. *Nat Genet* **51**, 1749-1755 (2019).

61   Das, S. *et al.* Next-generation genotype imputation service and methods. *Nat Genet* **48**, 1284-1287 (2016).

62   Giambartolomei, C. *et al.* Bayesian test for colocalisation between pairs of genetic association studies using summary statistics. *PLoS Genet* **10**, e1004383, https://doi.org/10.1371/journal.pgen.1004383 (2014).

63   Benner, C. *et al.* FINEMAP: efficient variable selection using summary data from genome-wide association studies. *Bioinformatics* **32**, 1493-1501 (2016).

64   Huffman, J. E. *et al.* Multi-ancestry fine mapping implicates OAS1 splicing in risk of severe COVID-19. *Nat Genet* **54**, 125-127 (2022).

65   Burgess, S., Daniel, R. M., Butterworth, A. S., Thompson, S. G. & Consortium, E. P.-I. Network Mendelian randomization: using genetic variants as instrumental variables to investigate mediation in causal pathways. *Int J Epidemiol* **44**, 484-495 (2015).

66   Carter, A. R. *et al.* Understanding the consequences of education inequality on
860   cardiovascular disease: mendelian randomisation study. *BMJ* **365**, l1855 (2019).
861   67   Hao, Y. *et al.* Integrated analysis of multimodal single-cell data. *Cell* **184**, 3573-3587 e29,
862   https://doi.org/10.1016/j.cell.2021.04.048 (2021).
863

Figure 1. Study overview.
MR: Mendelian randomization, BMI: body mass index, NPNT: nephronectin, HSD17B14:
hydroxysteroid 17-beta dehydrogenase 14, cis-pQTL: cis-acting quantitative trait loci, e-QTL:
expression quantitative trait loci, sQTL: splicing quantitative trait loci.

Figur   **body mass index on plasma protein levels.**

(a) Flow diagram of the Step 1 analyses. (b) Volcano plot illustrating the effect of BMI on each plasma protein from the MR analyses. Red and blue vertical lines represent $P = 1.0 \times 10^{-5}$ and 0.05, respectively. (c) MR scatter plot for the effect of BMI on plasma NPNT levels. (d) MR scatter plot for the effect of BMI on plasma HSD17B14 levels. A genetically predicted increase in BMI by one standard deviation was associated with increased levels of NPNT (beta = 0.145, 95% CI: 0.0841–0.206, $P = 3.03 \times 10^{-6}$) and HSD17B14 (beta = 0.14, 95% CI: 0.0848–0.202, $P = 1.70 \times 10^{-6}$) using the inverse variance weighted method. Sensitivity analyses with MR-Egger, weighted median, and weighted mode methods yielded directionally consistent results with the inverse variant weighted method.

MR: Mendelian randomization, BMI: body mass index, NPNT: nephronectin, HSD17B14: hydroxysteroid 17-beta dehydrogenase 14.

Figure 3. MR analyses of BMI-driven proteins on COVID-19 outcomes.

(a) Flow diagram of the Step 2 analyses. (b, c, d) Volcano plot illustrating the effect of BMI on severe COVID-19 (b), COVID-19 hospitalization (c), and COVID-19 susceptibility (d) from the MR analyses. Red and blue vertical lines represent P = 1.0 x 10^{-5} and 0.05, respectively. (e) Forest plot showing the MR results for NPNT and HSD17B14.

MR: Mendelian randomization, BMI: body mass index, NPNT: nephronectin, HSD17B14: hydroxysteroid 17-beta dehydrogenase 14, OR: odds ratio, 95% CI: 95% confidence intervals, P_{het} = P-value for heterogeneity test.

Figure 4. Colocalization analyses of cis-pQTL for NPNT and COVID outcomes in the 1-Mb

region around rs34712979.

PP_{shared}: Posterior probability that cis-pQTL for NPNT shares a single causal signal with the

COVID-19 outcome.

Figure 5. Colocalization analyses of cis-pQTL with sQTL and eQTL for NPNT.

899 PP_{shared}: Posterior probability that cis-pQTL for NPNT shares a single causal signal with its

900 sQTLs or eQTLs in the lung.

Exposures	Outcome		Beta (95% CI)	*P*-value
Body fat mass	Plasma NPNT levels		0.23 (0.13–0.33)	6.86 ×10^{-6}
Body fat-free mass	Plasma NPNT levels		-0.15 (-0.26, -0.04)	5.83×10^{-3}

Figure 6. Multivariable MR analysis for evaluating independent effects of body fat and fat-free mass on plasma NPNT levels.

MR: Mendelian randomization; NPNT: nephronectin.

Extended Figure 1. Colocalization analysis of the cis-pQTL for HSD17B14 and the COVID-
906
19 outcomes in the 1Mb region around rs150400299.
907

PP$_{shared}$: Posterior probability that the cis-pQTL for NPNT shares a single causal signal with
908
COVID-19 outcomes, 1Mb: one-megabase.
909

910
Extended Figure 2. MR mediation analysis illustrated by the directed acyclic graph.
Dark blue arrow represents the total effect of BMI on severe COVID-19. Red arrow represents
the effect of BMI on severe COVID-19 mediated by NPNT. The NPNT-mediated effect can be
calculated by multiplying $\beta_{\text{BMI-to-NPNT}}$ and $\beta_{\text{NPNT-to-severity}}$, where $\beta_{\text{BMI-to-NPNT}}$ is the effect of BMI on
NPNT and $\beta_{\text{NPNT-to-severity}}$ is the effect of NPNT on severe COVID-19 adjusted for BMI.
MR: Mendelian randomization; NPNT: nephronectin.

Extended Figure 3. NPNT expression levels in lung cell types from COVID-19 lung

autopsy samples.

(a) NPNT expression levels of each cell type at the single-cell resolution in the 16 lung donors

with COVID-19. (b) 28 annotated cell types of the lung. (c) NPNT expression status in SARS-

CoV-2 non-infected cells (viral infection −, top panel) or SARS-CoV-2 infected cells (viral

infection +, bottom panel). NPNT expression levels of 28 cell types in the two groups are shown

in a box plot. In each box, the horizontal line denotes a median value of the expression levels,

and the asterisk inside each box denotes the mean value. Each box extends from the 25th to

the 75th percentile of each group. Log(TP10K+1) was calculated by normalizing original gene

counts by total unique molecular identifiers (UMI) counts, multiplying by 10,000 (TP10K), and

then taking the natural logarithm.